Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 7,061 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- matched Clear all

Conditions: Stable Angina, Metabolic Syndrome
Interventions: Ranolazine, Placebo; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Attention Deficit/Hyperactivity Disorder
Interventions: centanafadine capsule, placebo capsule; Drug · Other
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Acute Mountain Sickness
Interventions: ambrisentan and theophylline, placebo; Drug
Lead sponsor: University of Montana; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Otherwise Healthy Overweight or Obese
Interventions: PHP-303, Placebo; Drug · Other
Lead sponsor: pH Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency
Interventions: Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule, Cohort 2 CTAP101 Capsules - 30µg, Cohort 2 Matching Sugar Capsule; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Covid19
Interventions: BGB-DXP593, Placebo; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more

Conditions: Post Menopausal Osteoporosis
Interventions: Placebo, Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 65 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Beverly Hills, California • La Jolla, California • Augusta, Georgia + 4 more

Conditions: Alzheimer's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio

Conditions: Healthy Volunteer
Interventions: A-005, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Breast Cancer
Interventions: Everolimus, Exemestane, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 63
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Anaheim, California + 54 more

Conditions: Pancreatic Cancer
Interventions: Simtuzumab, Gemcitabine, Placebo to match simtuzumab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 44
States / cities: Birmingham, Alabama • Mobile, Alabama • Alhambra, California + 40 more

Conditions: Cardiovascular Diseases, Hyper-LDL-cholesterolemia
Interventions: lerodalcibep; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: BIIB061, Placebo, 14C-BIIB061; Drug
Lead sponsor: Biogen; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Evansville, Indiana • Madison, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Stiolto Respimat, Placebo Respimat; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 45 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Torrance, California

Conditions: Healthy
Interventions: JNJ-70033093, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pantothenate Kinase-Associated Neurodegeneration
Interventions: Deferiprone oral solution, Placebo; Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 4 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: RSV Infection
Interventions: EDP-938, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 31
States / cities: Tempe, Arizona • Fresno, California • Lomita, California + 26 more

Conditions: Tourette's Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more

Conditions: Influenza A
Interventions: VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 129
States / cities: Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more

Conditions: Eosinophilic Esophagitis
Interventions: APT-1011, Placebo; Drug
Lead sponsor: Adare Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 51
States / cities: Chandler, Arizona • Tucson, Arizona • Sherwood, Arkansas + 45 more

Conditions: Schwannomatosis, Schwannomas, Pain, Chronic
Interventions: Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pruritus, Burns
Interventions: Serlopitant, Placebo; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Gainesville, Florida + 4 more

Search by objective public record fields.

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Drug Combination on Exercise Performance at High Altitude

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

Rasagiline Rescue in Alzheimer's Disease Clinical Trial

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury